Compare Biogen Inc (BIIB) vs GE Vernova Inc (GEV) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

GE Vernova (GEV) trades at $1,042.98, up 5.26% over 24 hours, reflecting strong momentum near its pivot point of $1,017. The stock exhibits bullish technical signals with moving averages supporting the uptrend. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $17.44 significantly exceeding expectations, though Q2 2026 saw a miss. Revenue growth is solid, projected to rise from $38.07B in 2025 to $41.4B in 2026, while net income margin expanded to 23.04%. The company benefits from a massive $176 billion backlog, positioning it to capitalize on AI-driven power demand.

Outlook remains positive given GEV's strategic role in addressing AI infrastructure bottlenecks, but high valuations (P/E 29.01, EV/EBITDA 86.33) pose risks if execution falters. Analyst consensus is strongly bullish with a $1,270 price target, though investors should monitor quarterly execution against lofty expectations and competitive pressures in the energy sector.